The purpose of this study is to determine if a treatment by bumetanide presents an efficiency at the level of the neuronal maturation in the autism
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
60
Administration by oral route in 2 times (in the morning and evening) of 0.5 mg by taking (= 1 mg by 24 hours)
Lemonnier
Brest, France
Chevreuil
Rennes, France
DUPIN
Vannes, France
Child Autism Rating Scale score
Time frame: day 0 to day 90
Clinical global impressions score
Time frame: day 0 to day 90
Repetitive end restricted behavior score
Time frame: day 0 to day 90
GRAM score
Time frame: day 0 to day 90
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.